The results indicate that there is a decrease in the expression of FOXO3a protein and a reduction in the transcriptional activity of FOXO3a in CRC cells that harbor KRAS/BRAF mutations as well as in CRC cells that have developed resistance to cetuximab treatment. This evidence concerns the gene BRAF and colorectal carcinoma.